¿Qué posibles vacunas contra el Covid-19 estan siendo probadas?
(What vaccine candidates are being tested for covid-19?)
Primeras 5 respuestas:
-
roxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or).
-
inactivated vaccine, subunit protein vaccine, nucleic acid vaccine, adenoviral vector vaccine, and recombinant influenza viral vector vaccine.
-
Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines.
-
The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.
-
Most vaccine candidates are developed from recombinant DNA and mRNA, or inactivated whole-virus (IWV) [41] .
roxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or).
The pulmonary surfactant-biomimetic nanoparticles used to potentiate heterosubtypic 152 influenza immunity can be used as adjuvant to enhance the immunogenicity of 153 SARS-CoV-2 subunit vaccines [33] . roxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or).
Ref: Current development of COVID-19 diagnostics, vaccines and therapeutics [Microbes Infect, 2020-05-06]inactivated vaccine, subunit protein vaccine, nucleic acid vaccine, adenoviral vector vaccine, and recombinant influenza viral vector vaccine.
... by the Chinese Health Commission indicated that at least five vaccine technologies will be explored: inactivated vaccine, subunit protein vaccine, nucleic acid vaccine, adenoviral vector vaccine, and recombinant influenza viral vector vaccine. With the growing size of the domestic vaccine industry in recent years, China vaccine developers ...
Ref: Timely development of vaccines against SARS-CoV-2 [Emerg Microbes Infect, 2020-03-08]Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines.
... Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this ...
Ref: Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure [J Infect Dis, 2020-03-31]The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.
... protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19. ...
Ref: Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study [J Biomol Struct Dyn, 2020]Most vaccine candidates are developed from recombinant DNA and mRNA, or inactivated whole-virus (IWV) [41] .
... vaccines are currently under development and some have begun to be tested on healthy volunteers. Most vaccine candidates are developed from recombinant DNA and mRNA, or inactivated whole-virus (IWV) [41] . Given the close genetic relationship between SARS-CoV and SARS-CoV-2, the current SARS-CoV-2 vaccines may provide ...
Ref: Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials [Cureus, 2020-05-28]An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial.
... is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high ...
Ref: Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 [Microb Pathog, 2020]S protein or RBD subunit vaccines and replicating or non-replicating vector vaccines expressing mainly S protein or the RBD.
... Currently, there may be many promising targets for SARS-CoV-2. COVID-19 candidate vaccines under development include S protein or RBD subunit vaccines and replicating or non-replicating vector vaccines expressing mainly S protein or the RBD. Several studies showed that viral S protein subunit vaccines displayed higher neutralizing antibody titers and ...
Ref: A review on Promising vaccine development progress for COVID-19 disease [Vacunas, 2020-06-13]At least 110 vaccine candidates are in preclinical testing and at least 5 vaccines have already begun early clinical testing 4 .
... academic institutions across the planet have launched a multifaceted vaccine development response with unprecedented rapidity. At least 110 vaccine candidates are in preclinical testing and at least 5 vaccines have already begun early clinical testing 4 . The focus of the response is haste, understandably so, leading to use of novel technologies, ...
Ref: Universal coronavirus vaccines: the time to start is now [NPJ Vaccines, 2020-05-28]Three vaccine candidates have already advanced to Phase II testing that include an mRNA vaccine encoding the viral spike (S) protein from Moderna,
... virus, virus like particles, and protein subunits (Thanh Le et al., 2020; WHO, 2020b) . Three vaccine candidates have already advanced to Phase II testing that include an mRNA vaccine encoding the viral spike (S) protein from Moderna, an Adeno-type 5 vector vaccine expressing the S protein from CanSino Biologicals, and a chimpanzee ...
Ref: Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19 [Cell, 2020-05-27]Two vaccine candidates, Covid-19/aAPC vaccine and LV-SMENP-DC vaccine,
... the genetically modified APCs may potentially activate a strong protective immunity against infections [75] . Two vaccine candidates, Covid-19/aAPC vaccine and LV-SMENP-DC vaccine, which were made by modifying artificial APCs and dendritic cells with LVs expressing multiple viral ...
Ref: Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines [Biomed J, 2020-05-30]i) An adenovirus type-5 vector-based vaccine, and ii) an LNP-encapsulated mRNA vaccine.
... are moving at a rapid pace. Two candidate vaccines are in Phase I clinical trials: i) An adenovirus type-5 vector-based vaccine, and ii) an LNP-encapsulated mRNA vaccine. Studies evaluating the safety and immunogenicity of these vaccines are underway. Additionally, several vaccine candidates ...
Ref: Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 [Microb Pathog, 2020-05-04]Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc),
... novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 ...
Ref: Rapid development of an inactivated vaccine candidate for SARS-CoV-2 [Science (Wash.), 2020]Immunogenic peptides in viruses or bacteria that match human proteins are good candidates for pathogenic priming peptides
... MERS spike protein. Exposure pathogenesis to SARS-CoV-2 in COVID-19 likely will lead to similar outcomes. Immunogenic peptides in viruses or bacteria that match human proteins are good candidates for pathogenic priming peptides (similar to the more diffuse idea of "immune enhancement"). Here I provide an assessment of ...
Ref: Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity [J Transl Autoimmun, 2020]Aluminum hydroxide (alum) is the most commonly used agent as an adjuvant.
... Aluminum hydroxide (alum) is the most commonly used agent as an adjuvant. The mechanism of its adjuvant action is complex and, so far, multiple hypotheses have been put forward to explain its mode of action [153] . It has been shown to ...
Ref: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses [J Transl Autoimmun, 2020-06-18]The first vaccine that does not follow all research steps is called mRNA-1273 and will be tested in the first phase in Seattle.
... The first vaccine that does not follow all research steps is called mRNA-1273 and will be tested in the first phase in Seattle. There is an explanation for the speed of approval, which is related to the fact that the coronavirus is not used in the vaccine development. It is an experimental vaccine, ...
Ref: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review) [Int J Mol Med, 2020-05-06]nucleotide, subunit and vector based as well as attenuated and inactivated forms,
... to SARS-CoV and MERS-CoV proteins. In this review we have summarized various vaccine candidates i.e., nucleotide, subunit and vector based as well as attenuated and inactivated forms, which have already been demonstrated their prophylactic efficacy against MERS-CoV and SARS-CoV, so these candidates ...
Ref: Vaccination strategies to combat novel corona virus SARS-CoV-2 [Life Sci, 2020-06-12]none of the non-structural proteins have been evaluated as 232 vaccine candidates.
... predicted second-highest protective antigenicity score, adhesin property, promiscuous 222 of the viral structural particle, and none of the non-structural proteins have been evaluated as 232 vaccine candidates. The SARS/MERS/COVID-19 vaccine studies so far target the structural 233 (S/M/N) proteins. Still, the non-structural ...
Ref: COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning [bioRxiv, 2020-03-21]The engineered vaccine sequence is adjuvanted with ß-3 defensin and comprised of B-cell epitopes, HTL epitopes and CTL epitopes.
... biology and advanced immunoinformatic strategies to devise a multi-epitope subunit vaccine against ongoing COVID-19 infection. The engineered vaccine sequence is adjuvanted with ß-3 defensin and comprised of B-cell epitopes, HTL epitopes and CTL epitopes. This is very likely that the vaccine will be able to elicit the strong immune ...
Ref: High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19 [Eur J Pharm Sci, 2020-05-14]Peptides containing two out of the nine sites were tested as vaccine candidates against SARS-CoV-2 in a mouse model.
... (RBD). Further analysis showed that these ID sites are potential high-affinity SARS-CoV-2 antibody binding sites. Peptides containing two out of the nine sites were tested as vaccine candidates against SARS-CoV-2 in a mouse model. We detected epitope-specific antibodies and SARS-CoV-2-neutralising activity in the immunised mice. This study for the ...
Ref: Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19 [bioRxiv, 2020-04-27]Akiko Iwasaki 1,2 ✉ and Yexin Yang 1
... Akiko Iwasaki 1,2 ✉ and Yexin Yang 1 There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an ...
Ref: The potential danger of suboptimal antibody responses in COVID-19 [Nat Rev Immunol, 2020-04-21]whole killed virus, subunit, attenuated, viral vector, DNA and mRNA vaccines.
... of March, there were at least 68 vaccine candidates comprising several different vaccine designs, including whole killed virus, subunit, attenuated, viral vector, DNA and mRNA vaccines. Whilst it usually takes 10-15 years to develop a vaccine, it has only taken just ...
Ref: [At least 68 vaccine candidates under development]. [Lakartidningen, 2020-04-06]mRNA-1273 Modified mRNAs are synthetic molecules optimized for high-level and durable protein expression.
... these vaccines have advanced to human trials without data in animals establishing efficacy against COVID-19. mRNA-1273 Modified mRNAs are synthetic molecules optimized for high-level and durable protein expression. This technology has shown promise as a vaccine platform for influenza virus (NCT03076385 and NCT03345043) ...
Ref: The Challenges of Vaccine Development against a New Virus during a Pandemic [Cell Host Microbe, 2020-05-13]A single-plasmid DNA vaccine encoding the Spike (S) glycoprotein was evaluated in 10 healthy adults.
... safety and immunogenicity of a SARS DNA vaccine in a Phase I human study. METHODS: A single-plasmid DNA vaccine encoding the Spike (S) glycoprotein was evaluated in 10 healthy adults. Nine subjects completed the 3 dose vaccination schedule and were evaluated for vaccine safety and ...
Ref: A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial [Vaccine, 2008-11-01]The vaccine candidates encompass a large diversity of vaccine platforms including mRNA, DNA, nanoparticle, subunit, and viral vectors 8 .
... to elicit polyclonal antibody responses against the spike protein of SARS-CoV-2 to neutralize viral infection. The vaccine candidates encompass a large diversity of vaccine platforms including mRNA, DNA, nanoparticle, subunit, and viral vectors 8 . Some of the new technological platforms, such as DNA and mRNA vaccines, can theoretically enable ...
Ref: Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development [EBioMedicine, 2020-04-16]Remdesivir, Lopinavir, Ritonavir, and Oseltamivir significantly blocked the COVID-19 infection in infected patients.
... evaluated either alone or in combinations to treat COVID-19 patients, mice models, and clinical isolates. Remdesivir, Lopinavir, Ritonavir, and Oseltamivir significantly blocked the COVID-19 infection in infected patients. It can be cocluded that the homologus recombination event at the S protein of RBD ...
Ref: COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses [J Adv Res, 2020-03-16]prefilled single dose syringes, single or multidose vials, nasal spray, micropatches or other delivery devices.
prefilled single dose syringes, single or multidose vials, nasal spray, micropatches or other delivery devices.
Ref: Emerging Manufacturers engagements in the COVID -19 vaccine research, development and supply [Vaccine, 2020-06-11]Multiple vaccine candidates against SARS-CoV-2 based on viral spike protein are under development.
... Multiple vaccine candidates against SARS-CoV-2 based on viral spike protein are under development. However, there is limited information on the quality of antibody responses generated with these vaccine modalities. To better understand antibody responses induced by spike protein-based vaccines, we performed a qualitative ...
Ref: Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits [Sci. transl. med, 2020]Vaccines such as DNA vaccine, mRNA vaccine, and recombinant vaccines are being rapidly developed.
... antivirals, and AMPs. For COVID-19, candidates mainly include drugs targeting the S protein, nonstructural proteins (3CLpro, PLpro, helicase, and RdRp), and viral RNA synthesis blockers such as Remdesivir and Ribavirin. Vaccines such as DNA vaccine, mRNA vaccine, and recombinant vaccines are being rapidly developed. ...
Ref: Overview of lethal human coronaviruses [Signal Transduct Target Ther, 2020-06-10]cell membrane fusion, RNA-dependent RNA polymerase, viral protease inhibitor, interleukin 6 blocker, and convalescent plasma
... Some candidate drugs targeting different levels and stages of human responses against COVID-19 such as cell membrane fusion, RNA-dependent RNA polymerase, viral protease inhibitor, interleukin 6 blocker, and convalescent plasma may improve the clinical outcomes of critical COVID-19 patients. Other supportive care measures for critical ...
Ref: Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines [Biomed. j. (Mumbai.Online), 2020]DNA vaccine, mRNA vaccine, inactivated whole virus vaccine, and adenovirus-vectored vaccine,
... al., 2020) . Thus far, a number of SARS-CoV-2 vaccine candidates derived from different vaccine platforms, including DNA vaccine, mRNA vaccine, inactivated whole virus vaccine, and adenovirus-vectored vaccine, have rapidly progressed into clinical trials (Amanat and Krammer, 2020; Callaway, 2020; . ...
Ref: Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement [bioRxiv, 2020-05-21]We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses,
... COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate ...
Ref: Immunogenicity of a DNA vaccine candidate for COVID-19 [Nat Commun, 2020]ChAdOx1 nCoV-19
... Institute and Merck KGaA have developed a manufacturing process for the institute’s COVID-19 vaccine candidate, ChAdOx1 nCoV-19 Using technology developed by Merck, the partners have reduced the process development phase from 12 ...
Ref: Merck KGaA helps scale COVID-19 vaccine [C&EN Global Enterprise, 2020]The immunogenicity of a candidate-inactivated vaccine prepared from SARS-CoV F69 strain was evaluated in Balb/c mice.
... The immunogenicity of a candidate-inactivated vaccine prepared from SARS-CoV F69 strain was evaluated in Balb/c mice. Potent humoral immune responses were induced under the elicitation of three times of immunizations at 2-week intervals with this vaccine, combined with three types of adjuvants (Freund"s adjuvant, Al(OH)(3) adjuvant ...
Ref: Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain [Vaccine, 2005-05-02]To generate a COVID-19 vaccine candidate, we therefore attempted to display the RBD domain on CuMVTT (Fig. 1a) .
... as atopic dermatitis in dogs or insect bite hypersensitivity in horses [9] [10] [11] . To generate a COVID-19 vaccine candidate, we therefore attempted to display the RBD domain on CuMVTT (Fig. 1a) . To this end we gene-synthesized the COVID-19 RBD domain and fused it to an Fc ...
Ref: Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles [bioRxiv, 2020-05-14]inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al.
... immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is ...
Ref: [Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)] [Zhonghua Yu Fang Yi Xue Za Zhi, 2020]The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate.
... developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to ...
Ref: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review [Zhonghua Yu Fang Yi Xue Za Zhi, 2020]Recombinant L. plantarum may provide a promising food-grade oral vaccine candidate against SARS-CoV-2 infection.
... ng/mL SppIP at 37 °C for 6-10 h. The recombinant spike (S) protein was stable under normal conditions and at 50 °C, pH = 1.5, or a high salt concentration. Recombinant L. plantarum may provide a promising food-grade oral vaccine candidate against SARS-CoV-2 infection. ...
Ref: A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2 [Int J Biol Macromol, 2020]As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials.
... virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy ...
Ref: [Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)] [Zhonghua Yu Fang Yi Xue Za Zhi, 2020]While multiple candidate vaccines are currently under different stages of development, there are no known therapeutic interventions at the moment.
... converting enzyme 2 and is considered as the antigenic determinant for stimulating an immune response. While multiple candidate vaccines are currently under different stages of development, there are no known therapeutic interventions at the moment. This review describes the key genetic features that are being considered for generating vaccine candidates ...
Ref: Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus. [Journal of biosciences, 2020]A recombinant modified vaccinia virus Ankara vaccine expressing the full length MERS CoV spike protein produced neutralizing antibody in immunized mice.
... vaccines also target the spike protein. Approaches have included subunit proteins, DNA, and gene-based vectors. A recombinant modified vaccinia virus Ankara vaccine expressing the full length MERS CoV spike protein produced neutralizing antibody in immunized mice. 63 Subsequently, Ma and coworkers focused on the receptor binding domain (RBD) of the MERS ...
Ref: Vaccines for Emerging Viral Diseases [The Vaccine Book, 2016-07-15]we concentrated the inactivated avian influenza pseudovirus as immunogens to 301 raise antisera against avian influenza HA and NA structural proteins in mice.
... raising antibody by 299 structural protein expressing recombinant protein subunit vaccine in SARS-CoV-2 300 virus, we concentrated the inactivated avian influenza pseudovirus as immunogens to 301 raise antisera against avian influenza HA and NA structural proteins in mice. We 302 determined neutralization antibody titers of raised antisera against different subtypes 303 of influenza ...
Ref: Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development [Biomed J, 2020-06-06]The vaccine industry was able to develop H1N1 vaccine fairly rapidly because the technology and regulations were already in place to develop influenza vaccine.
... There is an urgent need to expedite the development of COVID-19 vaccine. The vaccine industry was able to develop H1N1 vaccine fairly rapidly because the technology and regulations were already in place to develop influenza vaccine. Global experiences with influenza vaccines have outlined the urgency for investing in modern technologies for faster vaccine development ...
Ref: Coronavirus Vaccine: Light at the End of the Tunnel [Indian Pediatr, 2020-04-15]Lopinavir and Ritonavir were used in preliminary clinical studies [3] .
Lopinavir and Ritonavir were used in preliminary clinical studies [3] .
Ref: Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19) [Microb Pathog, 2020-05-05]Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies.
... decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed ...
Ref: COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics [Hum Vaccin Immunother, 2020]There are no effective vaccines or specific antiviral drugs for COVID-19.
... are searching for effective and suitable vaccine candidates and therapeutics for controlling the deadly COVID-19. There are no effective vaccines or specific antiviral drugs for COVID-19. Hence, we have to rely exclusively on enforcing strict preventive and control measures that minimize ...
Ref: COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics [Hum Vaccin Immunother, 2020-03-18]inactivated vaccine, recombinant subunit vaccine, recombinant vector vaccine, and nucleic acid vaccine.
... (hCoV). There are several types of vaccines are under pre-clinical testing or clinical trials including inactivated vaccine, recombinant subunit vaccine, recombinant vector vaccine, and nucleic acid vaccine. In general, modern vaccines, such as recombinant subunit, peptide, and nucleic acid vaccines, are advantageous ...
Ref: COVIEdb: A database for potential immune epitopes of coronaviruses [bioRxiv, 2020-05-25]There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials.
... morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful ...
Ref: Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines [Vaccine, 2020]certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically 11 .
... 9 . However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically 11 . The DNA and mRNA vaccines that are easier to design and proceed into clinical trials ...
Ref: The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines [NPJ Vaccines, 2020-03-06]considering various drugs for possible treatments and prophylaxis.
... virus - with vaccine trials underway in the US and the United Kingdom - and considering various drugs for possible treatments and prophylaxis. Here, we provide an overview of SARS-CoV-2 by analyzing its virology, epidemiology, and modes of ...
Ref: A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2 [FEBS j, 2020]An epitope-based peptide vaccine has been raised in this aspect.
... membrane protein during viral assembly affects host cell responses including cell cycle and translation . An epitope-based peptide vaccine has been raised in this aspect. The core mechanism of the peptide vaccine is based on the chemical method to synthesize ...
Ref: Epitope-Based Peptide Vaccine Against Severe Acute Respiratory Syndrome-Coronavirus-2 Nucleocapsid Protein: An in silico Approach [bioRxiv, 2020-05-17]The vaccine candidate against spike viral surface glycoprotein of SARS-CoV-2 was designed by in silico methods.
... The vaccine candidate against spike viral surface glycoprotein of SARS-CoV-2 was designed by in silico methods. The epitopes predicted with different web servers and adjuvant linkers were used to construct a potent antigenic, nonallergenic vaccine that could elicit strong immune response against SARS-CoV-2. Docking analysis provided ...
Ref: Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study [J Biomol Struct Dyn, 2020-06-01]a randomly selected SARS-CoV-2 sequence could be used as a vaccine candidate 20
... we focused on the S protein, our comparative analyses of other proteins yielded similar conclusions: a randomly selected SARS-CoV-2 sequence could be used as a vaccine candidate 20 given the typical similarity of any sequence to the computationally derived optimum sequence (as defined ...
Ref: A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains [bioRxiv, 2020-04-27]We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein,
... COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build ...
Ref: Immunogenicity of a DNA vaccine candidate for COVID-19 [Nat Commun, 2020]recombinant-protein based vaccines, replicating or non-replicating viral vector-based vaccines, DNA vaccines, and mRNA vaccines
... Many vaccine candidates are in rapid development, including recombinant-protein based vaccines, replicating or non-replicating viral vector-based vaccines, DNA vaccines, and mRNA vaccines (which mostly have focused on the spike glycoprotein or receptor binding domain), live attenuated vaccines, and inactivated virus vaccines. All of these ...
Ref: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial [Lancet, 2020-05-22]vectored vaccines, oral vaccines, subunit vaccines, inactivated vaccines, peptide-based vaccines, nucleotide-based vaccine, etc.
... 2020, at least 115 SARS-CoV-2 vaccine projects have been announced to be in development, including vectored vaccines, oral vaccines, subunit vaccines, inactivated vaccines, peptide-based vaccines, nucleotide-based vaccine, etc. Several SARS-CoV-2 vaccine candidates have recently been approved for clinical phase I or II development ...
Ref: mRNA Vaccines: Possible Tools to Combat SARS-CoV-2 [Virol Sin, 2020-06-10]Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines.
... workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines. Summary: Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that ...
Ref: The SARS-CoV-2 Vaccine Pipeline: an Overview [Curr Trop Med Rep, 2020]For one mRNA-based candidate, a clinical trial recently started to enroll volunteers shortly (ClinicalTrials.gov: NCT04283461).
... vaccine platforms have been developed, and for some of them, pre-clinical experiments have been initiated. For one mRNA-based candidate, a clinical trial recently started to enroll volunteers shortly (ClinicalTrials.gov: NCT04283461). However, many additional steps are needed before these vaccines can be used in the population, ...
Ref: SARS-CoV-2 Vaccines: Status Report [Immunity, 2020-04-06]SARS-CoV, inactivated by means of formaldehyde, UV light, or beta-propiolactone,
... SARS-CoV, inactivated by means of formaldehyde, UV light, or beta-propiolactone, was able to protect mice from infection in challenge studies [16] [17] [18] . In analogy, for MERS, a recombinant, propagation-defective live virus lacking the structural envelope protein gene has ...
Ref: Vaccine Development Against Middle East Respiratory Syndrome [Curr Trop Med Rep, 2016-07-11]An mRNA-based vaccine, a relatively recent technology, is being tested for COVID-19 in phase I clinical trials [128]
... SARS and MERS coronavirus in clinical trials, other vaccine platforms are yet to be tested. An mRNA-based vaccine, a relatively recent technology, is being tested for COVID-19 in phase I clinical trials [128] with other companies starting clinical trials soon as of April 11 of the year of ...
Ref: cord_uid qu7ddcw9 Vaccines for SARS-CoV-2: Lessons from Other Co... qu7ddcw9 Vaccines for SARS-CoV-2: Lessons from Other Co... Name: title, dtype: object [Curr Trop Med Rep, cord_uid qu7ddcw9 2020-04-23 qu7ddcw9 2020-04-23 Name: publish_time, dtype: object]any vaccine candidates from China—
... resources into unprecedented comparative studies in animals, fast-tracked human trials, and manufacturing Eschewing international cooperation—and any vaccine candidates from China— it hopes to have 300 million doses by January 2021 of a proven product, reserved ...
Ref: Unveiling ‘Warp Speed,’ the White House’s America-first push for a coronavirus vaccine [Science, 2020]In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein
... by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, ...
Ref: DNA vaccine protection against SARS-CoV-2 in rhesus macaques [Science (Wash.), 2020]Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity,
... up the establishment of a variety of vaccine platforms. Accordingly, numerous vaccines are under development. Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity, and most of these candidates have recently moved into clinical trials. Before the efficacy of ...
Ref: Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines [Biomed. j. (Mumbai.Online), 2020](1) the antiviral drug remdesivir that is known to inhibit RNA dependent RNA polymerase,
... the clinical trials. The trials aim to test the effectiveness of the four potential candidates: (1) the antiviral drug remdesivir that is known to inhibit RNA dependent RNA polymerase, (2) a combination of two HIV drugs, lopinavir and ritonavir, (3) lopinavir and ritonavir plus ...
Ref: Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials [J Biosci, 2020-06-12]Initially, whole inactivated virus (WIV) or modified vaccinia virus Ankara expressing SARS vaccines were developed [1] ,
... Initially, whole inactivated virus (WIV) or modified vaccinia virus Ankara expressing SARS vaccines were developed [1] , however, eosinophilic immunopathology was observed in mice and non-human primates immunized with these viral-vectored vaccines [2] [3] [4] [5] [6] [7] . Even though historically there have been reports that ...
Ref: Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement [bioRxiv, 2020-05-22]ChAdOx1 nCoV-19 Using technology developed by Merck,
... Institute and Merck KGaA have developed a manufacturing process for the institute’s COVID-19 vaccine candidate, ChAdOx1 nCoV-19 Using technology developed by Merck, the partners have reduced the process development phase from 12 months to 2 A trial ...
Ref: Merck KGaA helps scale COVID-19 vaccine [C&EN Global Enterprise, 2020]We used purified recombinant spike antigens to immunize female New Zealand White rabbits.
... this study was to investigate humoral immune response following vaccination with different SARS-CoV-2 spike immunogens. We used purified recombinant spike antigens to immunize female New Zealand White rabbits. Due to time, funding, and staffing restrictions during the COVID-19 pandemic, we began the exploratory ...
Ref: Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits [Sci Transl Med, 2020-06-08]Live attenuated vaccines (LAV) are viruses that are rendered replication-incompetent through repeated passage in cell culture,
... Live attenuated vaccines (LAV) are viruses that are rendered replication-incompetent through repeated passage in cell culture, and inactivated vaccines utilise whole pathogen which has typically been killed by exposure to chemicals (e.g. formaldehyde) or heat inactivation (33) . LAV are immunogenic and reproduce the breadth of ...
Ref: The early landscape of COVID‐19 vaccine development in the UK and rest of the world [Immunology, 2020-05-27]Some of them will be tested in Phase I trials in the weeks to come [4] .
... vaccines is a crucial challenge, and several candidates are currently under basic development [3] . Some of them will be tested in Phase I trials in the weeks to come [4] . The time it takes to develop a vaccine is estimated to be 1 or 1.5 ...
Ref: Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic [Immunology, 2020-04-27]Vaccines have included inactivated whole virus vaccines, live attenuated virus DNA vaccines, viral vector vaccines, subunit vaccines, and DNA vaccines.
... Most vaccines have been directed at developing anti-S neutralizing antibody responses. Vaccines have included inactivated whole virus vaccines, live attenuated virus DNA vaccines, viral vector vaccines, subunit vaccines, and DNA vaccines. DNA vaccines were shown to induce anti-S antibodies in mice and were later shown to induce virus-specific neutralizing antibody ...
Ref: MIDDLE EAST RESPIRATORY SYNDROME VACCINES [International Journal of Infectious Diseases, 2016-06-01]remdesivir, baricitinib, and chloroquine for the treatment of this disease.
... has greatly facilitated the global effort to develop a vaccine for prevention of COVID-19. Also shown in this table are journal articles pertaining to potential antiviral drug candidates such as remdesivir, baricitinib, and chloroquine for the treatment of this disease. ...
Ref: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases [ACS Cent Sci, 2020-03-12]We first generated codon optimized MERS-S1 subunit vaccines fused with a foldon trimerization domain to mimic the native viral structure.
... envelope, is considered a key target for vaccines for the prevention of coronavirus infection. METHODS: We first generated codon optimized MERS-S1 subunit vaccines fused with a foldon trimerization domain to mimic the native viral structure. In variant constructs, we engineered immune stimulants (RS09 or flagellin, as TLR4 or TLR5 agonists, ...
Ref: Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development [EBioMedicine, 2020-04-02]In this review we have summarized various vaccine candidates i.e., nucleotide, subunit and vector based as well as attenuated and inactivated forms,
... of viral structural and nonstructural proteins which are very similar to SARS-CoV and MERS-CoV proteins. In this review we have summarized various vaccine candidates i.e., nucleotide, subunit and vector based as well as attenuated and inactivated forms, which have already been demonstrated their prophylactic efficacy against MERS-CoV and SARS-CoV, so these candidates ...
Ref: Vaccination strategies to combat novel corona virus SARS-CoV-2 [Life Sci, 2020-06-12]we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein
... virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, ...
Ref: DNA vaccine protection against SARS-CoV-2 in rhesus macaques [Science (Wash.), 2020]Plasma transfusion and herbal medicine were also considered to control this new coronavirus.
... detection besides the CT imaging. Many potential vaccine candidates and drugs are tested against COVID-19. Plasma transfusion and herbal medicine were also considered to control this new coronavirus. Due to the absence of effective treatment or vaccines against COVID-19 so far, the precautionary ...
Ref: An overview on COVID-19: reality and expectation [Bull Natl Res Cent, 2020-06-01]The licensed Group B meningococcus Bexsero vaccine, which was developed via 245 reverse vaccinology, contains three protein antigens 9 .
... vaccine includes more than one antigen to cover different aspects of 244 protection 39,40 . The licensed Group B meningococcus Bexsero vaccine, which was developed via 245 reverse vaccinology, contains three protein antigens 9 . To develop an efficient and safe COVID-19 246 cocktail vaccine, it is possible to mix ...
Ref: COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning [bioRxiv, 2020-03-21]The vaccines included whole inactivated virus vaccines (Roberts et al., 2010) , purified expressed spike protein, DNA vaccine encoding the spike protein ,
... Roberts et al., 2010) , and non-human primates (reviewed in Roberts et al., 2008) . The vaccines included whole inactivated virus vaccines (Roberts et al., 2010) , purified expressed spike protein, DNA vaccine encoding the spike protein , and several vectored vaccines (MVA, VSV, BHPIV3) expressing the spike protein (Buchholz et al., 2004) ...
Ref: SARS-CoV-2: A New Song Recalls an Old Melody [Cell Host Microbe, 2020-05-13]live viruses, recombinant protein subunits, and nucleic acids that may ultimately offer promise as preventive vaccines against COVID-19.
... There are now at least a half-dozen candidates, including live viruses, recombinant protein subunits, and nucleic acids that may ultimately offer promise as preventive vaccines against COVID-19. However, each of these vaccines may require additional manufacturing steps and formal toxicology testing before submitting a regulatory package to national ...
Ref: The SARS-CoV-2 Vaccine Pipeline: an Overview [Curr Trop Med Rep, 2020-03-03]an inactivated vaccine has 78 elicited strong antibodies which can neutralize multiple SARS-CoV-2 strains
... technologies are being developed, or pre-77 clinically or clinically being investigated 3 . Amongst these, an inactivated vaccine has 78 elicited strong antibodies which can neutralize multiple SARS-CoV-2 strains and can 79 partially or fully protect macaques against SARS-CoV-2 challenge 4 . A chimpanzee ...
Ref: A Scalable Topical Vectored Vaccine Candidate Against SARS-CoV-2 [bioRxiv, 2020-06-01]recombinant S-protein-based vaccines, attenuated and whole inactivated vaccines, and vectored vaccines (Roper and Rehm, 2009 ).
... Several vaccines for SARS-CoV-1 were developed and tested in animal models, including recombinant S-protein-based vaccines, attenuated and whole inactivated vaccines, and vectored vaccines (Roper and Rehm, 2009 ). Most of these vaccines protect animals from challenge with SARS-CoV-1, although many do not induce sterilizing immunity. In ...
Ref: SARS-CoV-2 Vaccines: Status Report [Immunity, 2020-04-06]RNA, DNA, protein subunit, vector, and inactivated vaccines.
... for COVID-19, including vaccine development [2] . There are currently about 60 vaccine candidates in the preclinical development stage, including RNA, DNA, protein subunit, vector, and inactivated vaccines. Several are currently in phase I clinical trials [3] . ...
Ref: Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic [Vaccine, 2020-04-20]neutralizing antibodies were elicited by B/HPIV3, VSV, rabies, MVA and adeno viruses expressing S protein,
... expressing SARS-CoV-1 proteins, it was shown that 8 viral proteins were expressed in mice, ferrets, and hamsters. In these studies, neutralizing antibodies were elicited by B/HPIV3, VSV, rabies, MVA and adeno viruses expressing S protein, that protected against SARS-CoV-1 replication in lungs of challenged animals. ...
Ref: Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines [Vaccine, 2020-05-25]Thirty-seven identified proteins in SARS-CoV-2 were evaluated.
... infection. This is achieved via bioinformatics analysis of the homology between highly immunogenic SARS-CoV-2 epitopes and human proteins to promote comprehension of the etiologies of pathogenesis of SARS-CoV-2 in COVID-19. Thirty-seven identified proteins in SARS-CoV-2 were evaluated. ...
Ref: Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity [Journal of Translational Autoimmunity, 2020-12-31]Some SARS-CoV-1 and MERS-CoV vaccine candidates appear to exacerbate illness in animals after subsequent viral challenge [7] .
... Yet, there is reason for caution as the experience in animal models is inconclusive. Some SARS-CoV-1 and MERS-CoV vaccine candidates appear to exacerbate illness in animals after subsequent viral challenge [7] . Such vaccine-enhanced disease harks back to respiratory syncytial virus (RSV) and dengue vaccines that caused harm. ...
Ref: Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development [J Infect Dis, 2020-05-04]Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described.
... like the possible treatment plans with drug (antiviral drugs and anti-cytokines) therapy for disease prevention. Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described. Collectively, the review provides an overview of the SARS-CoV-2 infection outbreak along with the recent ...
Ref: SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. [European review for medical and pharmacological sciences, 2020-04-01]the S2 subunit has potential 308 to be used as a target for the development of pan-CoV vaccine against divergent virus strains.
... sequences of 306 HR1 and HR2 are highly conserved and homologous between SARS-CoV and SARS-CoV-2. In fact, 307 these domains are also highly conserved in other coronaviruses (104) , thus the S2 subunit has potential 308 to be used as a target for the development of pan-CoV vaccine against divergent virus strains. ...
Ref: From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development [Microbes Infect, 2020-05-11]Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates.
... models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease ...
Ref: Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines [Vaccine, 2020]TLR4 agonist LPS/MPLA Induces SARS-CoV S-specific antibody and virus-specific antibody (>1:10 4 ) 118 .
TLR4 agonist LPS/MPLA Induces SARS-CoV S-specific antibody and virus-specific antibody (>1:10 4 ) 118 .
Ref: Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight [Acta Pharm Sin B, 2020-05-30]Seven vaccine candidates have 82 peptide was removed from the structure using Chimera 1.14
... available for SARS-CoV-2, although there are 81 over 100 vaccine candidates reportedly in development worldwide. Seven vaccine candidates have 82 peptide was removed from the structure using Chimera 1.14 (University of California-San Francisco) (50) 158 prior to running simulations. Ten models of each peptide-HLA ...
Ref: Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome [bioRxiv, 2020-05-14]The vaccine candidates will be developed by the DNA, recombinant and mRNA vaccine platforms from these organizations [109] .
... will fund vaccine development programmes with Inovio, The University of Queensland and Moderna, Inc respectively, with the aim to test the experimental vaccines clinically in 16 weeks (By June 2020). The vaccine candidates will be developed by the DNA, recombinant and mRNA vaccine platforms from these organizations [109] . ...
Ref: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review [J Clin Med, 2020-02-26]inactivated virus, lipid nanoparticle (LNP)-encapsulated mRNA, and plasmid DNA,
namely inactivated virus, lipid nanoparticle (LNP)-encapsulated mRNA, and plasmid DNA, are in phase I clinical trials
Ref: COVID‐19 vaccines: knowing the unknown [Eur J Immunol, 2020-05-21]Specifically, seven developed vaccines for the S protein of SARS-CoV-2
... and 367 ongoing clinical trials. Finally, only ten ongoing clinical trials met the inclusion criteria. Specifically, seven developed vaccines for the S protein of SARS-CoV-2 and three clinical trials assessed the protective role of BCG vaccine against COVID-19. The first ...
Ref: The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans. [Panminerva medica, 2020-05-26]Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein.
... Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following ...
Ref: Immunogenicity of a DNA vaccine candidate for COVID-19 [Nat Commun, 2020]RSV vaccine candidates.
... of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease ...
Ref: Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines [Vaccine, 2020]the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.
... and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19. ...
Ref: Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study [J Biomol Struct Dyn, 2020]Dendritic cells are a subset of APCs that can be modified to express and present antigens,
... antigen presenting cells (APCs) to induce cytotoxic T-cell responses in patients who have developed COVID-19. Dendritic cells are a subset of APCs that can be modified to express and present antigens, and this property has been used in phase I trials with tumour-associated and neo-antigen cancer ...
Ref: The early landscape of COVID‐19 vaccine development in the UK and rest of the world [Immunology, 2020-05-27]The first vaccine that does not follow all research steps is called mRNA-1273
... The first vaccine that does not follow all research steps is called mRNA-1273 and will be tested in the first phase in Seattle. There is an explanation for the speed of approval, which is related to the fact that the coronavirus is not ...
Ref: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review) [Int J Mol Med, 2020-05-06]civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2,
... were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2, and that domain 288-330 of S1 protein from the SARS-CoV-2 represents promising therapeutic and/or vaccine ...
Ref: Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target [F1000Res, 2020-04-27]Inovio Pharmaceuticals is developing a DNA vaccine,
... Acid Vaccines Several major biotechs have advanced nucleic acid vaccine platforms for COVID-19. For example, Inovio Pharmaceuticals is developing a DNA vaccine, while others, such as Moderna Therapeutics and Curevac, are • Suitable for adults > 60 ...
Ref: The SARS-CoV-2 Vaccine Pipeline: an Overview [Curr Trop Med Rep, 2020-03-03]An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease
... to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in ...
Ref: Ethical considerations for epidemic vaccine trials [J. med. ethics, 2020]We selected six proteins of COVID-19 virus ( Table 1) that have an essential role in virulence and replication of the virus,
... We selected six proteins of COVID-19 virus ( Table 1) that have an essential role in virulence and replication of the virus, and previous studies have highlighted the necessity of these proteins in coronaviruses function. After the antigenic analysis of these proteins, three proteins of N, ORF3a, and M were selected for ...
Ref: Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study [J Biomol Struct Dyn, 2020-05-02]